Physician profile
Brian W Pullam
NPI 1770121535
$2,899.40
in general payments reported to CMS, 2019-2025
47 companies · $566 in 2025
The $566 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $291 · 2023: $1,651 · 2024: $391 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,538 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,538.31 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $200.74 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $186.96 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $185.99 | 2023-2025 | Quviviq, Quviviq |
| Exelixis INC. | $178.00 | 2023-2025 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $143.54 | 2022-2024 | |
| Celgene Corporation | $136.54 | 2022-2023 | Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $134.85 | 2022-2023 | Keytruda, Lynparza, Welireg |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.11 | 2024-2025 | Caplyta |
| Genzyme Corporation | $113.60 | 2023 | |
| Astellas Pharma US INC | $100.90 | 2023 | Xtandi |
| Amgen INC. | $82.02 | 2022-2023 | Kyprolis |
| Regeneron Healthcare Solutions, INC. | $80.68 | 2023 | Libtayo |
| Lundbeck LLC | $78.44 | 2024-2025 | Rexulti |
| Janssen Biotech, INC. | $70.84 | 2022-2023 | Darzalex, Tecvayli, Erleada |
| Tris Pharma INC | $65.06 | 2024-2025 | Dyanavel Xr |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Pullam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.